Cagrilintide

Cagrilintide is a synthetic, long-acting analog of the pancreatic hormone amylin, engineered to overcome the practical limitations that make native amylin unsuitable as a medicine. Amylin, also called islet amyloid polypeptide, is released alongside insulin from pancreatic beta cells in response to meals and acts as a satiety signal that helps the body regulate food intake and blood glucose. Cagrilintide, developed under the codenames NN9838 and AM833, retains the biological activity of amylin while dramatically extending its duration of action.

Native amylin has two properties that prevent its direct use as a drug. First, it is highly amyloidogenic, meaning it tends to misfold and aggregate into insoluble deposits, the same process associated with islet damage in type 2 diabetes. Second, it is cleared from the bloodstream within minutes. Cagrilintide solves both problems: strategic substitutions in the peptide backbone suppress the aggregation tendency, and a lipid side chain (acylation) allows the molecule to bind reversibly to serum albumin, creating a circulating reservoir that releases the peptide slowly over days.

Cagrilintide belongs to a lineage that began with pramlintide, a short-acting non-aggregating amylin analog approved for use alongside insulin. Where pramlintide requires dosing at each meal, cagrilintide's albumin-binding design supports once-weekly administration, matching the convenience of modern weekly GLP-1 therapies. This pharmacokinetic profile is the key advance that makes amylin agonism practical for weight management research and positions cagrilintide as a partner molecule for combination obesity treatment.

Cagrilintide works by activating amylin receptors in the brain, reproducing and prolonging the natural satiety signaling of endogenous amylin. Amylin receptors are not single proteins but complexes formed when the calcitonin receptor pairs with accessory proteins called receptor activity-modifying proteins (RAMPs). These combinations create the AMY1, AMY2, and AMY3 receptor subtypes, which are concentrated in hindbrain regions that govern appetite and meal termination.

Central Satiety Signaling

Cagrilintide acts primarily in the area postrema and nucleus of the solitary tract, hindbrain structures that lie outside the tight blood-brain barrier and are therefore accessible to circulating hormones. Activation of amylin receptors in these regions promotes a sense of fullness, reduces meal size, and lengthens the interval between meals. This central mechanism distinguishes amylin analogs from drugs that work mainly on the gut or pancreas.

Complementarity With GLP-1

Cagrilintide is designed to pair with GLP-1 receptor agonists because the two hormones reduce appetite through parallel but separate circuits. GLP-1 signaling engages receptors in the hypothalamus and hindbrain and acts on the pancreas to enhance glucose-dependent insulin release, while amylin signaling works chiefly through the calcitonin-receptor complexes of the hindbrain. When both pathways are stimulated together, the appetite-suppressing effects add up, and research suggests amylin agonism may help sustain weight loss by influencing the body's defended weight set point.

Acylation and Half-Life

Cagrilintide's fatty acid side chain is the feature responsible for its weekly dosing. After injection, the lipid tail inserts into a binding pocket on albumin, the most abundant protein in blood plasma. Because albumin circulates for roughly three weeks, the bound peptide is protected from rapid kidney clearance and enzymatic breakdown, and it is released gradually to interact with amylin receptors. This same albumin-binding principle underlies several other long-acting peptide medicines.

Cagrilintide has been evaluated in a structured clinical development program spanning early dose-finding studies through large phase 3 trials, both as a single agent and as part of the CagriSema combination. The research consistently shows dose-dependent appetite suppression and weight loss.

Monotherapy Findings

Cagrilintide as a standalone weekly injection produced graded, dose-dependent reductions in body weight across its explored dose range in phase 2 research, with the higher doses generating placebo-adjusted weight loss in the range typically associated with effective single-agent obesity therapies. Participants also reported reduced hunger and increased satiety, consistent with the compound's central mechanism.

The CagriSema Combination

Cagrilintide combined with semaglutide, the fixed-dose regimen called CagriSema, is the most closely watched application of the compound. In phase 2 research the combination produced substantial weight loss that exceeded what either cagrilintide or semaglutide achieved individually, supporting the hypothesis that amylin and GLP-1 pathways act additively. This result advanced the combination into the large phase 3 REDEFINE program in obesity and type 2 diabetes.

Metabolic Effects

Cagrilintide research has examined effects beyond the scale, including improvements in glycemic measures and reductions in waist circumference. Because amylin slows gastric emptying and suppresses glucagon, the compound blunts post-meal glucose excursions, an effect of particular interest for people with type 2 diabetes. Investigators continue to study how much of the combination's benefit derives from amylin agonism specifically versus the established GLP-1 component.

Cagrilintide dosing information below reflects protocols used in clinical research and is provided for informational purposes, not as guidance for personal use. Cagrilintide is an investigational compound, and any administration should occur only within a properly supervised clinical or research setting.

Formulation and Route

Cagrilintide is formulated as a subcutaneous injection, delivered in development as a pre-filled pen similar to other weekly metabolic peptides. It is injected into the fatty tissue of the abdomen, thigh, or upper arm. Because the albumin-binding design gives it a roughly seven-day half-life, a single weekly injection maintains steady exposure without the daily or per-meal dosing that shorter-acting amylin analogs require.

Dose Escalation in Research

Cagrilintide protocols use gradual dose escalation to improve gastrointestinal tolerability, the same strategy used with GLP-1 medicines. Studies typically start at a low weekly dose and step up at scheduled intervals toward a maintenance dose.

Administration Practices

Cagrilintide has shown a tolerability profile in clinical research that is broadly consistent with other appetite-regulating peptides, with gastrointestinal effects predominating. Because the compound is still investigational, its long-term safety continues to be characterized.

Common Side Effects

Cagrilintide most frequently produces gastrointestinal symptoms, a direct consequence of slowed gastric emptying and central appetite signaling.

Considerations With Appetite-Regulating Peptides

Cagrilintide shares several theoretical considerations common to the broader class of gut and metabolic hormone therapies:

• Gallbladder events: Rapid or substantial weight loss of any kind can raise the risk of gallstones, a consideration monitored across obesity therapies
• Delayed gastric emptying: Slowed stomach emptying can affect the absorption timing of other oral medications and produce early fullness
• Hypoglycemia in combination: When used with insulin or insulin secretagogues, appetite-regulating agents can increase the risk of low blood glucose
• Hydration: Nausea and reduced intake can lead to dehydration if fluid intake falls too low

Monitoring in Research

Cagrilintide studies incorporate routine monitoring of gastrointestinal tolerability, metabolic markers, and weight trajectory, with dose adjustments guided by how each participant responds. As with related therapies, individuals with a history of pancreatitis, gallbladder disease, or certain endocrine conditions receive particular attention, and the compound is evaluated carefully in the context of any concurrent diabetes treatment.